Sanegene closes over $110 million series B to advance RNAi pipeline
Sanegene Bio has raised more than $110 million in a series B round to move its RNAi programs toward registration studies and broaden development across metabolic, cardiovascular and autoimmune diseases. The financing comes as global RNA-based medicines gain momentum and investors show renewed confidence in advanced delivery platforms.
The round was led by an unnamed industrial investor, joined by an international sovereign fund, China Biopharma, Legend Capital, and others. Eli Lilly (NYSE: LLY) made a strategic investment, while Hillhouse, Qiming and others also returned to support the company’s next phase.
Chief executive Weimin Wang said the round is an important moment for the business and will support late-stage global development. He added that the team plans to move additional candidates into clinical testing using its extrahepatic delivery technology, which aims to silence disease-driving genes with fewer doses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze